Abstract
10598 Background: Trabectedin (T) has shown objective response and disease stabilisation in 5%–10% and 30-40% of unselected patients with advanced soft tissue sarcoma (STS) failing prior anthracycl...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
